Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours Β· Estimated delivery Aug 14 - Aug 19
In adults with type 2 diabetes, treatment with tirzepatide 5 mg, 10 mg and 15 mg once weekly was associated with superior weight reduction from baseline compared with placebo, semaglutide 1 mg weekly, titrated insulin degludec, titrated insulin glargine and titrated insulin lispro as an add-on to insulin glargine
Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly and Company that functions as a triple incretin receptor agonist
Continue treatment beyond 3 months only if people achieve at least 5% loss from their initial body weight during the treatment
The canonical retinoic acid response element (RARE) in retinoic acid target genes is the direct repeat 5PuG(G/T)(T/A)CA3 separated by a spacer of five nucleotides
